Sue Park, MD
Medical Oncology · Middletown, NJNPI 1609118843
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $199 of the $233 with a category attached, or 85.2%. 7 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 52.2% of the total. 2025 is the largest year on record at $144, 2.4 times the $60 reported in 2019. That places this record below the midpoint for medical oncology clinicians in NJ, where the typical reported total is $1,937.
Across 7 payments — averaging $33.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$122
- Ipsen Biopharmaceuticals, Inc$28
- Daiichi Sankyo Inc.$23
- AstraZeneca$17
- Sanofi$17
- Servier Pharmaceuticals LLC$15
- plus $12 from 1 others
What the payments were for
- Food & beverage$19985%
- Education$3415%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 1 | $122 |
| Ipsen Biopharmaceuticals, Inc | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $23 |
| AstraZeneca | 1 | $17 |
| Sanofi | 1 | $17 |
| Servier Pharmaceuticals LLC | 1 | $15 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA HD$122
How this compares
$233 in reported general payments places this provider in the 20th percentile of 112 medical oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 51 | $788,429 |
| VerzenioAbemaciclib | 52 | $716,787 |
| Anastrozole | 223 | $3,341 |
| Exemestane | 22 | $2,553 |
| Tamoxifen Citrate | 50 | $1,222 |
| Letrozole | 45 | $733 |
| Dexamethasone | 11 | $376 |
| Ondansetron Hcl | 24 | $117 |
| Alendronate Sodium | 16 | $111 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Middletown
- Kelley CoffmanMiddletown$2K
- James McCloskeyHackensack$2.8M
- Jamie KoprivnikarHackensack$1.7M
- Andrew PecoraHackensack$1.2M
- David VesoleHackensack$726K
- Lori LeslieHackensack$665K
- Noa BiranHackensack$263K
- Robert AlterHackensack$232K
- Harry HarperHackensack$226K
- Tatyana FeldmanHackensack$193K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.